Mithra Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Mithra Pharmaceuticals has a total shareholder equity of €36.1M and total debt of €301.4M, which brings its debt-to-equity ratio to 834.3%. Its total assets and total liabilities are €432.5M and €396.4M respectively.
Key information
834.3%
Debt to equity ratio
€301.38m
Debt
| Interest coverage ratio | n/a |
| Cash | €29.30m |
| Equity | €36.13m |
| Total liabilities | €396.38m |
| Total assets | €432.50m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MITP.F's short term assets (€101.8M) do not cover its short term liabilities (€127.4M).
Long Term Liabilities: MITP.F's short term assets (€101.8M) do not cover its long term liabilities (€269.0M).
Debt to Equity History and Analysis
Debt Level: MITP.F's net debt to equity ratio (753.2%) is considered high.
Reducing Debt: MITP.F's debt to equity ratio has increased from 53.2% to 834.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MITP.F has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if MITP.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.